Thermo Fisher Scientific, a global leading company in science services, today announced the launch of the Gibco™ OncoPro™ tumor media kit. *, this is the first commercial medium specially developed for the structural amplification of patient-derived tumor bulbs or tumor organ structures for multiple types of cancer.

Although cancer is still one of the main causes of death ⁱⁿ the world, there are still some difficulties in introducing new cancer treatments for patients, of which up to 97% of the candidate drugs fail in clinical trials. The patient-derived tumor ball (i.e. the tumor cell culture obtained from individual patients) is closer to the donor tissue than the traditional two-dimensional cell model, which is expected to help researchers better simulate the disease and predict the patient's response to treatment, and further improve the success rate of clinical trials. However, due to complex culture requirements and the lack of commercially available media systems, the application of patient-derived tumor balls in cancer research is limited. The new ready-made, modular tumor culture medium kit launched by Thermo Fisher Scientific aims to make complex cancer models more feasible for researchers.

Brian Douglass, vice president and general manager of cell biology at Thermo Fisher Scientific, said: "The unpredictability of cancer poses significant scientific and clinical challenges for future discoveries and life-saving treatments for patients. Despite decades of progress in research, diagnosis and treatment, millions of patients and their families around the world are still waiting for a cure for cancer. We have developed a new OncoPro™ tumor culture medium kit so that the scientific community can make better use of the tumor ball model to introduce candidate drugs to the market faster and more cost-effectively.

Thermo Fisher is committed to supporting scientists to reveal tumor bulb workflows and programs. In addition to democratizing this workflow through Tumoroid Assay Development Services, an OncoPro tumor ball media system, tumor bulb detection and development services also support outsourcing screening and characterization. Customers can also take advantage of 7 unique OncoPro tumor cell lines, covering four different cancer indications such as colorectal cancer, lung cancer, endometrial cancer and breast cancer. In order to improve the convenience of use, the OncoPro tumor ball medium kit also includes scalable and automated suspension culture methods.

Dr. Erik Goka, vice president of biology at Revere Pharmaceuticals, said: "It is well known that tumor organs can predict clinical results, adverse events and drug resistance mechanisms better than established two-dimensional cell lines. The OncoPro tumor ball culture medium kit helps us seamlessly integrate the tumor ball into our research and drug discovery process. With the help of the tumor ball culture medium system, we can amplify all organoids in the same culture medium system, regardless of their tissue source. This culture medium system plays a key role in allowing us to introduce tumor-like organs into the laboratory for daily use."

Adhering to Thermo Fisher's mission of "helping customers build a healthier, cleaner and safer world", OncoPro tumor ball culture medium kit does not require a commercial license**.